Pulmonary Cell News Volume 11.12 | Mar 31 2022

    By
    Justin.choi
    -
    0
    16







    2022-03-31 | PULCN 11.12


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 11.12 – 31 March, 2022
    TOP STORY

    Human Distal Lung Maps and Lineage Hierarchies Reveal a Bipotent Progenitor

    Using a non-human primate model of lung injury with human organoids and tissue specimens, researchers showed that alveolar type-2 cells in regenerating lungs transiently acquired an alveolar type-0 state from which they could differentiate into either alveolar type-1 cells or respiratory bronchiole-secretory cells.
    [Nature]

    Abstract
    Try proven workflows for your hPSC culture. Click to request your offer now.
    PUBLICATIONSRanked by the impact factor of the journal

    A PI3Kγ Mimetic Peptide Triggers CFTR Gating, Bronchodilation, and Reduced Inflammation in Obstructive Airway Diseases

    In human bronchial epithelial cells, phosphoinositide 3-kinase γ (PI3Kγ) mimetic peptide induced unexpected cyclic adenosine monophosphate and protein kinase A elevations restricted to the vicinity of the CF transmembrane conductance regulator (CFTR).
    [Science Translational Medicine]

    Abstract

    Lung Type II Alveolar Epithelial Cells Collaborate with CCR2+ Inflammatory Monocytes in Host Defense against Poxvirus Infection

    The authors reported that vaccinia C7 was a crucial virulence factor that blocked activation of the transcription factor IRF3.
    [Nature Communications]

    Full Article

    Ultrastructural Insight into SARS-CoV-2 Entry and Budding in Human Airway Epithelium

    Investigators examined human airway epithelium infected with three different isolates of SARS-CoV-2 including the B.1.1.7 variant by transmission electron microscopy and tomography.
    [Nature Communications]

    Full Article

    SARS-CoV-2 Infection of Airway Cells Causes Intense Viral and Cell Shedding, Two Spreading Mechanisms Affected by IL-13

    To investigate viral spread, primary human airway epithelial cell cultures were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and host–virus interactions were examined via electron microscopy, immunohistochemistry, RNA in situ hybridization, and gene expression analyses.
    [Proceedings of the National Academy of Sciences of the United States of America]

    AbstractPress Release

    TRIM46 Activates AKT/HK2 Signaling by Modifying PHLPP2 Ubiquitylation to Promote Glycolysis and Chemoresistance of Lung Cancer Cells

    Investigators found that tripartite motif (TRIM) 46 promoted lung adenocarcinoma cell proliferation and cisplatin resistance by enhancing glycolysis.
    [Cell Death & Disease]

    Full Article

    The Expression of PD-1 Ligand 1 on Macrophages and Its Clinical Impacts and Mechanisms in Lung Adenocarcinoma

    In an in vitro study using lung cancer cell lines and human monocyte-derived macrophages, the conditioned medium from cancer cells was found to up-regulate programmed cell death-1 ligand 1 expression on macrophages via STAT3 activation.
    [Cancer Immunology Immunotherapy]

    Full Article

    Overexpressed Transient Receptor Potential Vanilloid 1 (TRPV1) in Lung Adenocarcinoma Harbours a New Opportunity for Therapeutic Targeting

    TRPV1 expression in tumor tissues, primary cells and cell lines of lung adenocarcinoma, as well as the mechanism mediating its hyperexpression were systematically studied.
    [Cancer Gene Therapy]

    Full Article

    The Cancer/Testis Antigen HORMAD1 Mediates Epithelial–Mesenchymal Transition to Promote Tumor Growth and Metastasis by Activating the Wnt/β-Catenin Signaling Pathway in Lung Cancer

    The authors demonstrated that HORMAD1 promoted the proliferation, migration and invasion of lung cancer cells both in vitro and in vivo by inducing epithelial–mesenchymal transition.
    [Cell Death Discovery]

    Full Article

    Heterogeneous Nuclear Ribonucleoprotein K Promotes the Progression of Lung Cancer by Inhibiting the p53-Dependent Signaling Pathway

    Inhibition of progression of lung cancer cells induced by heterogeneous nuclear ribonucleoprotein K-knockdown was dependent on activation of p53 by the p53/p21/cyclin D1 pathway.
    [Thoracic Cancer]

    Full Article

    MicroRNA-631 Deriving from Bone Marrow Mesenchymal Stem Cell Exosomes Facilitates the Malignant Behavior of Non-Small Cell Lung Cancer via Modulating the E2F Family of Transcription Factor 2/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway

    Researchers explored the potential mechanism of exosome-derived miR-631 targeting and regulating E2F family of transcription factor 2 to repress the malignant behavior of NSCLC cells.
    [Bioengineered]

    Full ArticleGraphical Abstract
    Survey results on the insights and hurdles of CRISPR genome editing.
    REVIEWS

    Effective Viral-Mediated Lung Gene Therapy: Is Airway Surface Preparation Necessary?

    Scientists cover the airway surface preparation strategies reported in literature, the advantages and disadvantages of each method, as well as a discussion about applying this concept in the clinic.
    [Gene Therapy]

    Full Article

    The Inflammasome NLRP3 as a Novel Therapeutic Target for Idiopathic Pulmonary Fibrosis (IPF)

    The authors review evidence of NOD-like receptor (NLR) P3 activation in IPF, of NLRP3 inhibition in different animal models of fibrosis, and highlight the recent advances in direct and indirect NLRP3 inhibitors.
    [American Journal of Pathology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Prometheus Biosciences Initiates Third Phase II Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

    Prometheus Biosciences, Inc. announced it has enrolled its first patient in the ATHENA-SSc-ILD trial, a placebo-controlled and statistically powered Phase II study of PRA023 in SSc-ILD.
    [Prometheus Biosciences, Inc.]

    Press Release

    Ribon Therapeutics Announces Initiation of Phase Ib/II Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung

    Ribon Therapeutics announced the first patient has been dosed in the Phase Ib/II study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung.
    [Ribon Therapeutics]

    Press Release
    FEATURED EVENT

    ISCT 2022 San Francisco Annual Meeting

    May 4 – 7, 2022
    San Francisco, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scholar – Translational Lung Cancer

    The Ohio State University – Columbus, Ohio, United States

    Postdoctoral Associate – Acute Lung Injury

    University of Pittsburgh School of Medicine – Pittsburgh, Pennsylvania, United States

    Principal Scientific Researcher – Cell and Tissue Genomics

    Genentech, Inc. – South San Francisco, California, United States

    Senior Associate Scientist – Biology

    Gilead Sciences – Foster City, California, United States

    Faculty Position – Lung Cancer

    Fred Hutchinson Cancer Research Center – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter